Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amylin Pharmaceuticals LLC    AMLN

SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsSector news 

Amylin: EU Approves Diabetes Treatment Byetta With Basal Insulin

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/23/2012 | 01:54pm CET

Amylin Pharmaceuticals Inc. (>> Amylin Pharmaceuticals, Inc.) and Eli Lilly & Co. (LLY) said the European Commission approved its type 2 diabetes treatment Byetta as an add-on therapy to basal insulin.

The drug makers said Byetta with titrated basal insulin improves glycemic control after meals, and common side effects include nausea, diarrhea, dizziness and headache.

Lilly and Amylin in November severed their nine-year-old partnership that was supposed to furnish a blockbuster treatment for diabetes but was instead plagued by disappointing sales, regulatory troubles and company disputes, The Wall Street Journal reported. Amylin agreed to pay $250 million to Lilly upfront and as much as $1.2 billion more from sales of a molecule called exenatide that lowers the blood sugar of diabetics. That molecule is in the drug Byetta.

Amylin on Friday said it will assume responsibility for exenatide-product commercialization outside of the U.S. on a market-by-market basis by the end of 2013. During the transition period, Amylin will work with Lilly on plans for markets outside the U.S.

Amylin and Lilly shares closed Thursday at $15.41 and $39.81, respectively. Both were inactive premarket.

 
   -By Melodie Warner, Dow Jones Newswires; 212-416-2283; melodie.warner@dowjones.com 

Stocks mentioned in the article : Amylin Pharmaceuticals, Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMYLIN PHARMACEUTICALS LLC
2012 AMYLIN PHARMACEUTICALS, INC. : Bristol-Myers Squibb and AstraZeneca Complete Exp..
2012DJEli Lilly To Record $1.26 Billion Benefit from Amylin
2012DJASTRAZENECA : Bristol-Myers Squibb Completes Purchase of Amylin
2012DJBristol-Myers Executive Charged With Insider Trading
2012DJBristol-Myers Executive Charged With Insider Trading
2012DJBristol-Myers Executive Charged With Insider Trading
2012 Bristol-Myers executive charged with insider trading
2012DJU.S. Charges Bristol-Myers Executive With Insider Trading
2012DJBristol-Myers Pension Executive Robert Ramnarine Arrested for Alleged Insider..
2012DJCARL ICAHN : Icahn Sounds the Alarm on Forest Labs
More news
Sector news : Biopharmaceuticals
01:25aDJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
12/02DJJOHNSON & JOHNSON : Jury Orders Johnson & Johnson to Pay More Than $1 Billion in..
12/01DJValeant Deal Talks Collapse Over Price -- WSJ
12/01DJCSL : Eyes Biggest Undertaking Yet in Heart Therapy Trial
More sector news : Biopharmaceuticals
Advertisement
Chart AMYLIN PHARMACEUTICALS LLC
Duration : Period :
Amylin Pharmaceuticals LLC Technical Analysis Chart | AMLN | US0323461089 | 4-Traders
Full-screen chart
Sector and Competitors
1st jan.Capitalization (M$)
AMYLIN PHARMACEUTICALS..0.00%0
BIOGEN INC-3.45%64 354
CSL LIMITED-6.94%33 396
ALEXION PHARMACEUTICAL..-36.04%27 360
BIOMARIN PHARMACEUTICA..-18.26%14 332
GRIFOLS SA-15.08%12 353
More Results